- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07868939
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Hubert Chen, MD
- Telefoonnummer: 8587044660
- E-mail: clinicaltrials@vikingtherapeutics.com
Studie Locaties
-
-
Arizona
-
Tucson, Arizona, Verenigde Staten, 85741
- Werving
- Viking Clinical Site #2020
-
Contact:
- Telefoonnummer: 520-333-4515
-
-
California
-
Lake Forest, California, Verenigde Staten, 92630
- Werving
- Viking Clinical Site #2015
-
Contact:
- Telefoonnummer: 714-550-9990
-
-
Florida
-
Ocoee, Florida, Verenigde Staten, 34761
- Werving
- Viking Clinical Site #2059
-
Contact:
- Telefoonnummer: 407-654-2724
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30329
- Werving
- Viking Clinical Site #2013
-
Contact:
- Telefoonnummer: 404-920-6201
-
-
Indiana
-
Evansville, Indiana, Verenigde Staten, 47714
- Werving
- Viking Clinical Site #2001
-
Contact:
- Telefoonnummer: 812-477-2760
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Werving
- Viking Clinical Site #2046
-
Contact:
- Telefoonnummer: 504-336-2667
-
Valparaiso, Indiana, Verenigde Staten, 46383
- Werving
- Viking Clinical Site #2009
-
Contact:
- Telefoonnummer: 219-464-8302
-
-
Minnesota
-
Richfield, Minnesota, Verenigde Staten, 55423
- Werving
- Viking Clinical Site #2004
-
Contact:
- Telefoonnummer: 952-922-7000
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39206
- Werving
- Viking Clinical Site #2029
-
Contact:
- Telefoonnummer: 770-330-4157
-
-
Missouri
-
Springfield, Missouri, Verenigde Staten, 65807
- Werving
- Viking Clinical Site #2028
-
Contact:
- Telefoonnummer: 504-338-0917
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87107
- Werving
- Viking Clinical Site #2052
-
Contact:
- Telefoonnummer: 505-243-1627
-
-
New York
-
Binghamton, New York, Verenigde Staten, 13905
- Werving
- Viking Clinical Site #2039
-
Contact:
- Telefoonnummer: 607-800-5777
-
-
Oregon
-
Medford, Oregon, Verenigde Staten, 97504
- Werving
- Viking Clinical Site #2023
-
Contact:
- Telefoonnummer: 541-858-1018
-
-
Rhode Island
-
East Greenwich, Rhode Island, Verenigde Staten, 02818
- Werving
- Viking Clinical Site #2002
-
Contact:
- Telefoonnummer: 401-739-9350
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29407
- Werving
- Viking Clinical Site #2044
-
Contact:
- Telefoonnummer: 843-432-2477
-
-
Tennessee
-
Hendersonville, Tennessee, Verenigde Staten, 37075
- Werving
- Viking Clinical Site #2030
-
Contact:
- Telefoonnummer: 504-339-0917
-
-
Texas
-
Abilene, Texas, Verenigde Staten, 79606
- Werving
- Viking Clinical Site #2031
-
Contact:
- Telefoonnummer: 325-400-1150
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Werving
- Viking Clinical Site #2011
-
Contact:
- Telefoonnummer: 206-536-3030
-
Spokane, Washington, Verenigde Staten, 99218
- Werving
- Viking Clinical Site #2042
-
Contact:
- Telefoonnummer: 509-505-6227
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥18 years of age at the time of signing the informed consent.
- Body mass index (BMI) ≥ 27 kg/m2
- Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
Exclusion Criteria:
-
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
-
Self-reported body weight change of 5% or more within 3 months of screening
-
Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
-
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
-
Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
-
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
-
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
-
Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
-
History of acute or chronic pancreatitis
-
Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo Assignment
Placebo comparator orally once daily |
Placebo comparator administered orally once daily |
|
Experimenteel: Active Assignment (Dose 1)
VK2735 Dose level 1 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Experimenteel: Active Assignment (Dose 2)
VK2735 Dose level 2 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Experimenteel: Active Assignment (Dose 3)
VK2735 Dose level 3 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Tijdsspanne: 68 weeks
|
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 |
68 weeks
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- VK2735-305
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .